Patent record for “Rapid, comprehensive and sensitive method for neoantigen screening from recurrent cancer mutations”. Owner: Nexcalibur Therapeutics, Corp. Publication or grant number: US 12,277,997 B1. Jurisdiction: United States.
document previewRecord notes
Patent record for “Rapid, comprehensive and sensitive method for neoantigen screening from recurrent cancer mutations”. Owner: Nexcalibur Therapeutics, Corp. Publication or grant number: US 12,277,997 B1. Jurisdiction: United States.
Protection type
Intellectual property right
Jurisdiction
United States
Owner
Nexcalibur Therapeutics, Corp
The record is positioned according to its exploitation status and the relevant stakeholder group.
Ownership, market scope, protection coverage, and readiness for the next step are the priority review points.
Advisory support connects technical, legal, and commercial perspectives into a usable record.
Related
Open a discussion to confirm disclosure level, partner fit, and transfer or valuation requirements.
2024 · Vietnam
Unclassified
